108 related articles for article (PubMed ID: 38810886)
1. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
Yao X; Matosevic S
Immunol Lett; 2024 May; 268():106881. PubMed ID: 38810886
[TBL] [Abstract][Full Text] [Related]
2. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
[TBL] [Abstract][Full Text] [Related]
3. Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC; Schmitt TM; Paulson KG; Vigneron N; Buenrostro D; Wagener FD; Voillet V; Martin L; Gottardo R; Bielas J; McElrath JM; Stirewalt DL; Pogosova-Agadjanyan EL; Yeung CC; Pierce RH; Egan DN; Bar M; Hendrie PC; Kinsella S; Vakil A; Butler J; Chaffee M; Linton J; McAfee MS; Hunter DS; Bleakley M; Rongvaux A; Van den Eynde BJ; Chapuis AG; Greenberg PD
Sci Transl Med; 2022 Feb; 14(631):eabg8070. PubMed ID: 35138909
[TBL] [Abstract][Full Text] [Related]
4. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
5. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
7. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
9. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.
Dao T; Korontsvit T; Zakhaleva V; Jarvis C; Mondello P; Oh C; Scheinberg DA
Oncoimmunology; 2017; 6(2):e1252895. PubMed ID: 28344864
[TBL] [Abstract][Full Text] [Related]
10. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
11. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract][Full Text] [Related]
12. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
13. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
[TBL] [Abstract][Full Text] [Related]
14. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
15. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
17. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
[TBL] [Abstract][Full Text] [Related]
18. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.
Borbulevych OY; Do P; Baker BM
Mol Immunol; 2010 Sep; 47(15):2519-24. PubMed ID: 20619457
[TBL] [Abstract][Full Text] [Related]
19. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
20. Understanding CD8
Nguyen TH; Tan AC; Xiang SD; Goubier A; Harland KL; Clemens EB; Plebanski M; Kedzierska K
Clin Transl Immunology; 2017 Mar; 6(3):e134. PubMed ID: 28435676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
